The DOI matches its Crossref record; 170 of the 173 references it cites were found in a registry or an index.
Latest approaches for the treatment of obesity
Abstract
Introduction Obesity is a body weight disorder characterized by excess adiposity that increases the risk for developing co-morbidities such as type 2 diabetes. A large medical need exists for new anti-obesity treatments capable of promoting 10% or greater weight loss, with minimal side effects. Areas covered The authors describe the application of monogenic forms of rare obesity and genome-wide association studies in selecting critical pathways for drug discovery. Furthermore, they review in detail several pathways and pharmacological targets in the central nervous system (e.g., the leptin-melanocortin axis, the opioid system, GLP-1/GLP-1 system, and FGF21/FGFR1c/β-Klotho axis) that play an important role in the regulation of feeding behavior and energy homeostasis. Special focus is given to new strategies that engage well-known targets via novel mechanisms in order to circumvent issues seen with previous drug candidates that failed in the clinic. Finally, the authors discuss the recent developments around fixed-dose combinations, targeted polypharmacology, and non-traditional combinations of drugs and devices. Expert opinion The future for new weight-loss approaches to treat obesity looks promising. Current therapies have shown modest effects on weight loss in the general obese population but will have greater impact in smaller homogeneous sub-populations of obese subjects using personalized medicine. Drug combinations that target multiple, complementary pathways have the po…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The leptin-melanocortin axis, the opioid system, glucagon-like peptide-1 (GLP-1)/glucagon-like peptide-1 receptor (GLP-1R) system, and fibroblast growth factor 21 (FGF21)/its receptor complex FGFR1c/β-klotho axis are several common pathways confirmed by researches and pharmacological targets that play an essential role in regulating energy balance and feeding behavior (2).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [2]
Citations
Cites
Leptin and the regulation of body weight in mammals
Friedman, J. M., & Halaas, J. L. (1998) · Nature · doi:10.1038/27376 · Cited by 5,405 · cited 1×
“Leptin, a peptide hormone secreted mainly by white adipose tissue, plays a key role in the control of metabolism [36] .”
Genetic studies of body mass index yield new insights for obesity biology
Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature · doi:10.1038/nature14177 · Cited by 4,534 · cited 2×
“A landmark study published in 2015 identified 97 BMI-associated loci in a large GWAS and metab-ochip meta-analysis, which included results from 322,154 and 17,072 subjects of European and non-European descent, respectively [33] .”
Frayling, T. M., Timpson, N. J., Weedon, M. N., Zeggini, E., Freathy, R. M., Lindgren, C. M., Perry, J. R. B., Elliott, K. S., Lango, H., Rayner, N. W., et al. (2007) · Science · doi:10.1126/science.1141634 · Cited by 4,531
Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity
Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J. P., Druart, C., Bindels, L. B., Guiot, Y., Derrien, M., Muccioli, G. G., Delzenne, N. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219451110 · Cited by 4,511 · cited 1×
“Attempts to modulate such bacterial populations through dietary addition of fer-mentable substrates (prebiotics) or specific bacterial species (probiotics) have shown potential for non-pharmacological approaches to improving metabolism [153,154] .”
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788 · cited 1×
“Preclinically, transfer experiments of human intestinal microbial communities into germ-free mice demonstrated that an “obese” microbiome directly confers greater adiposity to its recipient than a “lean” microbiome [149,156] .”
Role of leptin in the neuroendocrine response to fasting
Ahima, R. S., Prabakaran, D., Mantzoros, C., Qu, D., Lowell, B., Maratos-Flier, E., & Flier, J. S. (1996) · Nature · doi:10.1038/382250a0 · Cited by 3,117 · cited 1×
“Reduction of plasma leptin by prolonged caloric restriction during weight loss or by anti-obesity pharmacotherapy (e.g., treatment with exendin-4, a GLP-1R agonist, or pramlintide, an amylin agonist) is associated with improved leptin sensitivity in rodents and humans [42-44] .”
The Effect of Diet on the Human Gut Microbiome: A Metagenomic Analysis in Humanized Gnotobiotic Mice
Turnbaugh, P. J., Ridaura, V. K., Faith, J. J., Rey, F. E., Knight, R., & Gordon, J. I. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000322 · Cited by 3,058 · cited 2×
“Preclinically, transfer experiments of human intestinal microbial communities into germ-free mice demonstrated that an “obese” microbiome directly confers greater adiposity to its recipient than a “lean” microbiome [149,156] .”
Congenital leptin deficiency is associated with severe early-onset obesity in humans
Montague, C. T., Farooqi, I. S., Whitehead, J. P., Soos, M. A., Rau, H., Wareham, N. J., Sewter, C. P., Digby, J. E., Mohammed, S. N., Hurst, J. A., et al. (1997) · Nature · doi:10.1038/43185 · Cited by 2,936 · cited 1×
“3.1 Leptin pathway Individuals with homozygous loss-of-function mutations in the genes encoding leptin and the leptin receptor (LepR) have normal birth weight but exhibit rapid weight gain in the first few months of life, resulting in severe obesity [34,35] .”
InfluentialVrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F. W. M., Dallinga–Thie, G. M., Ackermans, M. T., Serlie, M. J., Oozeer, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.031 · Cited by 2,913 · cited 1×
“Obese individuals with metabolic syndrome exhibited improvements in insulin sensitivity within 6 weeks of inoculation of intestinal microbes from healthy lean individuals [155] .”
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index
MAGIC, Speliotes, E. K., on behalf of Procardis Consortium, Willer, C. J., Berndt, S. I., Monda, K. L., Thorleifsson, G., Jackson, A. U., Allen, H. L., Lindgren, C. M., et al. (2010) · Nature Genetics · doi:10.1038/ng.686 · Cited by 2,912
Research works printed but not linked: 13
- Shin JH, 2013, Diabetes Metab Syndr Obes, 6, 131
- 10.1371/journal.pgen.1000508 · DOI · Paper page
- Ravussin Y, 2011, Am J Physiol, 300, R1352
- 10.1210/jcem.87.5.8628 · DOI · Paper page
- 10.1210/endo.143.3.8669 · doi:10.1210/endo.143.3.8669 · Paper page
- Clemmensen C, 2015, EMBO Mol Med
- Fang S, 2015, Nat Med
- Psichas A, 2014, Int J Obes
- Chambers ES, 2014, Gut
- Allison C, 2006, Issues Emerg Health Technol, 1
- 10.1371/journal.pone.0049345 · DOI · Paper page
- 10.1124/jpet.113.204420 · DOI · Paper page
- 10.1126/scitranslmed.3004690 · DOI · Paper page
Cited by
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
“It then develops into a weight disorder called obesity, defined as a BMI ≥30 kg/m(2) (2).”
BackgroundObesity and Weight Loss in Idiopathic Intracranial Hypertension: A Narrative Review
Subramaniam, S., & Fletcher, W. A. (2016) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000448 · Cited by 152
Managing obesity through natural polyphenols: A review
Singh, M., Thrimawithana, T. R., Shukla, R., & Adhikari, B. (2020) · Future Foods · doi:10.1016/j.fufo.2020.100002 · Cited by 147
Guo, Z., Li, M., Cai, J., Gong, W., Liu, Y., & Liu, Z. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20064741 · Cited by 159
“To date, diet intervention [8], lifestyle modification [9], exercise [10], drugs [11], and the combination of the above [12–14] have been systematically applied to weight loss.”
Metadata
- Authors
- Jackson, V. M., Breen, D. M., Fortin, J.-P., Liou, A., Kuzmiski, J. B., Loomis, A. K., Rives, M.-L., Shah, B., & Carpino, P. A.
- Affiliations
- Pfizer (United States) (US)
- ORCID
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2015-05-12
- Volume
- 10
- Issue
- 8
- Pages
- 825-839
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2100482349
- Cited by
- 132
- References
- 173
- Citations by year
- 2026: 5 · 2025: 25 · 2024: 18 · 2023: 22 · 2022: 22 · 2021: 17 · 2020: 7 · 2019: 4 · 2018: 5 · 2017: 1 · 2016: 5 · 2015: 1
- FWCI
- 0.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- obesity treatment, anti-obesity drugs, monogenic obesity, genome-wide association study, opioid system, GLP-1 receptor, feeding behavior, energy homeostasis, fixed-dose combination, drug-device combination products, personalized medicine, subcutaneous drug delivery, weight loss
- MeSH terms
- Animals, Drug Therapy, Combination, Humans, Obesity, Drug Design, Weight Loss, Anti-Obesity Agents, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Latest approaches for the treatment of obesity. https://app.cochat.ai/papers/10.1517/17460441.2015.1044966
- The paper
- Jackson, V. M., Breen, D. M., Fortin, J.-P., Liou, A., Kuzmiski, J. B., Loomis, A. K., Rives, M.-L., Shah, B., & Carpino, P. A. (2015). Latest approaches for the treatment of obesity. Expert Opinion on Drug Discovery. https://doi.org/10.1517/17460441.2015.1044966
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.